KEARNY, NJ (February 28, 2006) - Proprietary Nutritionals Inc. (PNI) announced that a new multi-site study has been commissioned on Celadrin®, a natural ingredient for joint health, by its developer Imagenetix, Inc. Patients currently diagnosed with moderate to severe knee pain are now being enrolled in the study, which is expected to be completed later this summer. Patients will consume Celadrin or placebo in capsule form throughout the 60-day, double-blind, placebo-controlled trial.
Dr. Jay Udani, M.D., medical director of Medicus Research, a private clinical trials facility located in Northridge, CA, will serve as the project manager and principal investigator. Patients will be enrolled at two locations—Northridge, CA and Ellicot City, MD. Apart from his role at Medicus Research, Dr. Udani is also the medical director of the Northridge Hospital Integrative Medicine Program and an assistant clinical professor at the UCLA School of Medicine.
Celadrin is an all-natural compound that has undergone more than ten in-vitro and clinical studies to date. Published research has shown that people using Celadrin had significant improvement in knee range of motion and decreased knee pain, without side effects. This research has been published in internationally acclaimed peer reviewed journals including the Journal of Rheumatology.
Proprietary Nutritionals, Inc., a joint venture with Pharmachem Laboratories, Inc., is located in Kearny, NJ. PNI markets Celadrin® Joint Flexibility & Pain Relief, and other patented, scientifically proven, branded ingredients to the nutraceuticals industry. For further information, visit www.celadrin.com, or call 519/647-2071.
Based in San Diego, CA, Imagenetix Inc., a company focused on inflammation and inflammation-related markets. Visit www.imagenetix.net for more information, or call 858-674-8455.
Statements contained in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. In particular, any statements contained herein regarding expectations with respect to future sales and profitability, as well as product development and/or introductions, are subject to known and unknown risks, uncertainties, and contingencies, many of which are beyond the Company’s control, which may cause actual results, performance, or achievements to differ materially from those projected or implied in such forward-looking statements. Factors that might affect actual results, performance, or achievements include, among other things, overall economic and business conditions, the demand for the Company’s goods and services, and technological advances and competitive factors in the markets in which the Company competes. The Company operates in a highly competitive marketplace and the Company may incur significant loses in the future.